Cardio-respiratory monitoring device. It develops a wireless, non-invasive Cardio-Respiratory monitoring device that will help patients measure real-time heart function. The company is operating in stealth mode. Founded in 2015, headquartered in Los Angeles, United States. The company has raised $17.8M in funding at the series a stage. The team comprises 14 (Jun 30, 2026) employees. Backed by investors including Orlando Health, Colle Capital, Frontier Venture Capital, NIH. The company operates in the Cardiac and Vascular Disorders sector with additional focus on Wearable Technology and Wearable Technology. Its business model centers on Cardiac. Founded in 2015, headquartered in Los Angeles, United States. The company has raised $17.8M at the Series A stage. Backed by investors including Orlando Health, Colle Capital, Frontier Venture Capital, NIH, HHS and others.
Sensydia
Series ACardio-respiratory monitoring device. It develops a wireless, non-invasive Cardio-Respiratory monitoring device that will help patients measure real-time heart function. The company is operating in stealth mode. Founded in 2015, headquartered in Los Angeles, United States. The company has raised $17.8M in funding at the series a stage. The team comprises 14 (Jun 30, 2026) employees. Backed by investors including…
About
Business model
Wearable Technology > Health and Wellness Devices > Cardiac,
Disease Self Management > Cardiac and Vascular Disorders > Monitoring > Heart Health > Device > Wearable,
Healthcare IT > Value Based Care > Remote Monitoring > Hardware > Cardiology > Wearable,
Cardiac and Vascular Disorders > Medical Devices > Monitoring Devices > Hemodynamic Parameters > Home Based,
MassChallenge Batches > HealthTech > 2023
Institutional investors
Latest coverage
📰 Latest funding news — recent raises and deal signals across the ecosystem.
Investor directory
🗂️ Full list of active funds — filter by stage, check size, and geography.